|
| | 100TH GENERAL ASSEMBLY
State of Illinois
2017 and 2018 SB1604 Introduced 2/9/2017, by Sen. Chris Nybo - Linda Holmes SYNOPSIS AS INTRODUCED: |
| 5 ILCS 80/4.28 | | 5 ILCS 80/4.30 | | 225 ILCS 85/25 | from Ch. 111, par. 4145 |
|
Amends the Pharmacy Practice Act. Provides that if a physician
or other authorized prescriber does not prohibit drug product substitution, a pharmacist shall dispense a brand name drug product as a substitute for an unavailable nonbrand name drug product specified in the prescription. Provides that if the substitute drug product has a unit price greater than the unavailable drug product specified in the prescription, then the pharmacist shall dispense that substitute drug product at the lesser unit price of the drug product specified in the prescription. Amends the Regulatory Sunset Act to extend the repeal date for the Pharmacy Practice Act to January 1, 2020. Makes conforming changes. Effective immediately.
|
| |
| | A BILL FOR |
|
|
| | SB1604 | | LRB100 10123 RJF 20297 b |
|
|
1 | | AN ACT concerning regulation.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Regulatory Sunset Act is amended by changing |
5 | | Sections 4.28 and 4.30 as follows: |
6 | | (5 ILCS 80/4.28) |
7 | | Sec. 4.28. Acts
repealed on January 1, 2018. The following |
8 | | Acts are
repealed on January 1, 2018: |
9 | | The Illinois Petroleum Education and Marketing Act.
|
10 | | The Podiatric Medical Practice Act of 1987. |
11 | | The Acupuncture Practice Act. |
12 | | The Illinois Speech-Language Pathology and Audiology |
13 | | Practice Act. |
14 | | The Interpreter for the Deaf Licensure Act of 2007. |
15 | | The Nurse Practice Act. |
16 | | The Clinical Social Work and Social Work Practice Act. |
17 | | The Pharmacy Practice Act. |
18 | | The Home Medical Equipment and Services Provider License |
19 | | Act. |
20 | | The Marriage and Family Therapy Licensing Act. |
21 | | The Nursing Home Administrators Licensing and Disciplinary |
22 | | Act. |
23 | | The Physician Assistant Practice Act of 1987. |
|
| | SB1604 | - 2 - | LRB100 10123 RJF 20297 b |
|
|
1 | | (Source: P.A. 95-187, eff. 8-16-07; 95-235, eff. 8-17-07; |
2 | | 95-450, eff. 8-27-07; 95-465, eff. 8-27-07; 95-617, eff. |
3 | | 9-12-07; 95-639, eff. 10-5-07; 95-687, eff. 10-23-07; 95-689, |
4 | | eff. 10-29-07; 95-703, eff. 12-31-07; 95-876, eff. 8-21-08; |
5 | | 96-328, eff. 8-11-09.) |
6 | | (5 ILCS 80/4.30) |
7 | | Sec. 4.30. Acts repealed on January 1, 2020. The following |
8 | | Acts are repealed on January 1, 2020: |
9 | | The Auction License Act. |
10 | | The Community Association Manager Licensing and |
11 | | Disciplinary Act. |
12 | | The Illinois Architecture Practice Act of 1989. |
13 | | The Illinois Landscape Architecture Act of 1989. |
14 | | The Illinois Professional Land Surveyor Act of 1989. |
15 | | The Land Sales Registration Act of 1999. |
16 | | The Orthotics, Prosthetics, and Pedorthics Practice Act. |
17 | | The Perfusionist Practice Act.
|
18 | | The Pharmacy Practice Act. |
19 | | The Professional Engineering Practice Act of 1989. |
20 | | The Real Estate License Act of 2000. |
21 | | The Structural Engineering Practice Act of 1989. |
22 | | (Source: P.A. 96-610, eff. 8-24-09; 96-626, eff. 8-24-09; |
23 | | 96-682, eff. 8-25-09; 96-726, eff. 7-1-10; 96-730, eff. |
24 | | 8-25-09; 96-855, eff. 12-31-09; 96-856, eff. 12-31-09; |
25 | | 96-1000, eff. 7-2-10.) |
|
| | SB1604 | - 3 - | LRB100 10123 RJF 20297 b |
|
|
1 | | Section 10. The Pharmacy Practice Act is amended by |
2 | | changing Section 25 as follows:
|
3 | | (225 ILCS 85/25) (from Ch. 111, par. 4145)
|
4 | | (Section scheduled to be repealed on January 1, 2018)
|
5 | | Sec. 25. No person shall compound, or sell or offer for |
6 | | sale, or
cause to be compounded, sold or offered for sale any |
7 | | medicine or preparation
under or by a name recognized in the |
8 | | United States Pharmacopoeia
National Formulary, for internal |
9 | | or external use, which differs from
the standard of strength, |
10 | | quality or purity as determined by the test
laid down in the |
11 | | United States Pharmacopoeia National Formulary official at
the |
12 | | time
of
such compounding, sale or offering for sale. Nor shall |
13 | | any person
compound, sell or offer for sale, or cause to be |
14 | | compounded, sold,
or offered for sale, any drug, medicine, |
15 | | poison, chemical or pharmaceutical
preparation, the strength |
16 | | or purity of which shall fall below the professed
standard of |
17 | | strength or purity under which it is sold. Except as set forth |
18 | | in Section 26 of this Act, if the physician
or other authorized |
19 | | prescriber, when transmitting an oral or written
prescription, |
20 | | does not prohibit drug product selection, a different
brand |
21 | | name or nonbrand name drug product of the same generic name may
|
22 | | be dispensed by the pharmacist, provided that the selected drug
|
23 | | has
a unit price less than the drug product specified in the |
24 | | prescription. If a physician
or other authorized prescriber |
|
| | SB1604 | - 4 - | LRB100 10123 RJF 20297 b |
|
|
1 | | does not prohibit drug product substitution, a pharmacist shall |
2 | | dispense a brand name drug product as a substitute for an |
3 | | unavailable nonbrand name drug product specified in the |
4 | | prescription. If the substitute drug product has a unit price |
5 | | greater than the unavailable drug product specified in the |
6 | | prescription, then the pharmacist shall dispense that |
7 | | substitute drug product at the lesser unit price of the drug |
8 | | product specified in the prescription.
A generic drug |
9 | | determined to be therapeutically equivalent by the
United |
10 | | States Food and Drug Administration (FDA) shall be
available |
11 | | for substitution in Illinois in accordance with this
Act and |
12 | | the Illinois Food, Drug and Cosmetic Act, provided that
each |
13 | | manufacturer submits to the Director of the Department of |
14 | | Public Health a notification containing product
technical |
15 | | bioequivalence information as a prerequisite to product
|
16 | | substitution when they have completed all required testing to
|
17 | | support FDA product approval and, in any event, the information
|
18 | | shall be submitted no later than 60 days prior to product
|
19 | | substitution in the State.
On the prescription forms of |
20 | | prescribers,
shall be placed a signature line and the words
|
21 | | "may not substitute". The prescriber, in his or her own |
22 | | handwriting,
shall place a mark beside "may not substitute"
to |
23 | | direct
the pharmacist in the dispensing of the prescription.
|
24 | | Preprinted or rubber stamped marks, or other deviations from
|
25 | | the above prescription format shall not be permitted. The |
26 | | prescriber
shall sign the form in his or her own handwriting to |
|
| | SB1604 | - 5 - | LRB100 10123 RJF 20297 b |
|
|
1 | | authorize the
issuance of the prescription.
|
2 | | In every case in which a selection is made as permitted by |
3 | | the Illinois
Food, Drug and Cosmetic Act, the pharmacist shall |
4 | | indicate on the pharmacy
record of the filled prescription the |
5 | | name or other identification
of the manufacturer of the drug |
6 | | which has been dispensed.
|
7 | | The selection of any drug product by a pharmacist shall not |
8 | | constitute
evidence of negligence if the selected nonlegend |
9 | | drug product was of
the same dosage form and each of its active |
10 | | ingredients did not vary
by more than 1 percent from the active |
11 | | ingredients of the prescribed,
brand name, nonlegend drug |
12 | | product. Failure of a prescribing
physician to specify that |
13 | | drug product selection is prohibited does not
constitute |
14 | | evidence of negligence
unless that practitioner has reasonable |
15 | | cause to believe that the health
condition of the patient for |
16 | | whom the physician is prescribing warrants
the use of the brand |
17 | | name drug product and not another.
|
18 | | The Department is authorized to employ an analyst or |
19 | | chemist of recognized
or approved standing whose duty it shall |
20 | | be to examine into any claimed
adulteration, illegal |
21 | | substitution, improper selection, alteration,
or other |
22 | | violation hereof, and report the result of his investigation,
|
23 | | and if such report justify such action the Department shall |
24 | | cause the
offender to be prosecuted.
|
25 | | (Source: P.A. 94-936, eff. 6-26-06; 95-689, eff. 10-29-07.)
|
26 | | Section 99. Effective date. This Act takes effect upon |